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Dendritic cells (DCs) are a heterogeneous group of professional antigen presenting cells functioning 
as sentinels of the immune system and playing a key role in the initiation and amplification of innate 
and adaptive immune responses. DC development and functions are acquired during a complex 
differentiation and maturation process influenced by several factors present in the local milieu. A 
common feature at pathologic sites is represented by hypoxia, a condition of low pO2 which creates a 
unique microenvironment affecting cell phenotype and behavior. Little is known about the impact of 
hypoxia on the generation of mature (m)DCs. In this study, we identified by gene expression profiling a 
significant cluster of genes coding for immune-related cell surface receptors strongly upregulated by 
hypoxia in monocyte-derived mDCs and characterized one of such receptors, TREM-1, as a new 
hypoxia-inducible gene in mDCs. TREM-1 associated with DAP12 in hypoxic mDCs, and its 
engagement elicited DAP12-linked signaling, resulting in ERK-1, Akt, and IBαphosphorylation and 
pro-inflammatory cytokine and chemokine secretion. Finally, we provided the first evidence that 
TREM-1 is expressed on mDCs infiltrating the inflamed hypoxic joints of children affected by Juvenile 













Dendritic cells (DCs) are a heterogeneous group of professional antigen-presenting cells involved in the 
initiation and amplification of innate and adaptive immunity, which develop through different 
haematopoietic pathways1. Myeloid DC immunostimulatory properties are acquired during a complex 
differentiation and maturation process. Their precursors extravasate from the bloodstream to non-
lymphoid peripheral tissues, where they reside in an “immature” stage (iDCs) at sites of potential 
pathogen entry, and are an important component of the leukocyte infiltrate in inflammatory tissues 1,2. 
iDCs are specialized for antigen capture and processing, functioning as sentinels of the immune system3. 
Antigen uptake and activation by endogenous factors, such as proinflammatory cytokines and tissue 
damage-associated molecular patterns (DAMPs), or exogenous factors, such as pathogen-associated 
molecular patterns (PAMPs), induce iDCs to undergo phenotypic and functional changes that culminate 
in their maturation into mDCs, which have a higher capacity for antigen presentation1. mDCs switch 
their chemokine receptor repertoire down-regulating inflammatory receptors and upregulating those 
required for homing to secondary lymphoid organs, where they prime naive T cells triggering specific 
immune responses2-4. The local microenvironment contributes to the regulation of DC development and 
functions 2,5,6. A common feature of inflamed tissues is represented by hypoxia, a condition of low 
partial oxygen pressure (pO2, 0-20mm Hg) which arises as a result of dysfunctional vascular network 
and diminished O2 supply and affects the phenotype and functions of every cell exposed to it 6-9. 
Activation of gene transcription is the primary mechanism by which mammalian cells respond to 
decreased pO2, and the underlying molecular pathways have been elucidated in detail and extensively 
reviewed. Briefly, transcriptional activation is mediated primarily by the hypoxia inducible factor-1 
(HIF-1), a heterodimer of the constitutive HIF-1βsubunit and an oxygen sensitive αsubunit (HIF-1α-
2α. αsubunits are post-translationally stabilized under hypoxia and translocate to the nucleus where 
they dimerize with HIF-1βtransactivating the hypoxia responsive element (HRE) present in the 
promoter of many O2-sensitive genes 7,8,10. HIF-1 expression and activity is tightly regulated by various 
cofactors and transcription factors, and HIF-independent pathways mediating gene induction by hypoxia 
have also been described 6,10,11. 
Recent studies have investigated hypoxia effects on DC differentiation, maturation, and functions. We 
reported that monocyte differentiation into iDCs under chronic hypoxia promotes the onset of a unique 
migratory phenotype by differentially modulating the expression profile of chemokines/receptors and 
genes involved in cell adhesion and tissue remodeling 12,13. Other studies indicated that acute iDC 
exposure to low pO2 may either impair 14 or promote 5,15 their maturation, by affecting expression of 
chemokine receptors, costimulatory molecules, and T cell priming ability. However, the impact of 
chronic hypoxia on mDC development and functional behaviour in inflammatory states is still largely 
unknown. 
In this study, we demonstrate that the gene expression pattern of mDCs generated from human 
monocytes under chronic hypoxia (H-mDCs) is distinct from that of mDCs developing under normal O2 
levels and characterized by upregulation of genes coding for surface costimulatory and adhesion 
molecules, immunoregulatory and pattern recognition receptors (PRRs). Among them, we identify the 
triggering receptor expressed on myeloid cells (TREM)-1, a member of the Ig superfamily of 
immunoreceptors and a strong amplifier of the immune responses 16,17, as a new hypoxia-inducible gene 
in mDCs. We provide evidence that this receptor is biologically active and expressed in vivo on mDCs 
recruited to the hypoxic joints of Juvenile Idiopatic Arthritis (JIA) patients, pointing to a pathogenetic 











DC generation and culture 
Blood monocytes were isolated from healthy volunteers at a purity of >93%, plated into sixwell culture 
plates (BD-Falcon) in RPMI 1640 (Euroclone) supplemented with 10% heatinactivated FCS (HyClone), 
and incubated for 4 days under normoxic (20% O2) or hypoxic (1% O2) conditions in the presence of 
GM-CSF and IL-4 (both 100 ng/ml), as detailed 12,13. A cocktail of proinflammatory mediators 
containing TNF(50 ng/ml), IL-1β(50 ng/ml), IL-6 (10 ng/ml), and PGE2 (1mM) was added for the last 
48hr to induce DC maturation. Hypoxic conditions were obtained by culturing cells in an anaerobic 
work-station incubator (CARLI Biotec) flushed with a mixture of 1% O2, 5% CO2, and 94% N2. 
Medium was allowed to equilibrate in the hypoxic incubator for 2hr before use, and pO2 was monitored 
using a portable oxygen analyzer (Oxi 315i/set, WTW). 
Synovial fluid mononuclear cell isolation 
Synovial fluid (SF) samples were obtained at the time of therapeutic knee arthrocentesis from eight 
children affected by oligoarticular JIA 18 and collected into sodium-heparin tubes under vacuum. pO2 
levels in SF samples were monitored to confirm hypoxic conditions. Paired PB samples and PB from 
five age-matched control subjects undergoing venepuncture for minor orthopedic procedures were 
obtained on the occasion of routine venepuncture and collected as for SF. Informed consent was 
obtained according to the procedure approved by the Gaslini’s Ethical Committee. Specimens were 
centrifuged to prepare cell-free SF and plasma and separated by Ficoll to isolate mononuclear cells 
(SFMCs and PBMCs). SF-derived samples were handled in the anaerobic incubator to prevent cell 
reoxygenation, as detailed 19,20. 
Cytokines and antibodies 
Human recombinant GM-CSF, IL-4, TNFα, IL-1β, and IL-6 were from PeproTech; PGE2 was from 
Sigma.  
mAbs used for FACS: anti-CD83-FITC or PE-Cy5 and anti-CD86-FITC (BD-Pharmingen), anti-
TREM-1-PE, anti-CXCR4-FITC, and anti-CCR7-FITC (R&D Systems), anti-CD1a-FITC or -APC 
(Serotec), anti-CD1-FITC and anti-CD141-APC (Miltenyi-Biotec). Proper isotype-matched control Abs 
(Dako) were used. 
Abs used for western blot: mouse anti-human TREM-1 (R&D Systems), mouse anti-human HIF-
1α(BD-Biosciences), rabbit anti-human phospho (p)-ERK)-1, p-Akt, and p-IkBα(Cell Signaling 
Technology), mouse anti-human DAP12, rabbit anti-human ERK-1, Akt, IkBαand β-actin (SantaCruz 
Biotechnology), 
Flow cytometry 
Flow cytometry was performed as described12,13. Cells resuspended with PBS supplemented with 0.2% 
BSA, 0.01% NaN3 were incubated with fluorochrome-conjugated mAbs for 30 min at 4°C, after 
blocking nonspecific sites with rabbit IgG (Sigma). Fluorescence was quantitated on a FACSCalibur 
flow cytometer equipped with CellQuest software (BD-Biosciences). Cells were gated according to their 
light-scatter properties to exclude cell debris. 
RNA isolation and GeneChip hybridization 
Total RNA was purified from different donor-derived mDCs using the Qiagen RNeasy MiniKit and 
reverse-transcribed into double-stranded cDNA on a GeneAmp PCR System 2700 thermal cycler 
(Applied Biosystems) using the one-cycle cDNA synthesis kit (Affymetrix). cDNA derived from three 
donors was purified and biotin labeled with the IVT-expressed kit (Affymetrix), as described21. 
Fragmented cRNA was hybridized to Affymetrix HG-U133 plus 2.0 arrays  (Genopolis Corporation) 
containing 54,000 probe sets coding for 38,500 genes, chips were stained with streptavidin-
phycoerythrin (Invitrogen) and scanned using an Affymetrix GeneChip Scanner 3000, as described 21. 
Data capturing was conducted with standard Affymetrix analysis software algorithms (Microarray Suite 
5.0). Comparative analysis of hypoxic relative to normoxic expression profiles was carried out with 
GeneSpring Expression Analysis Software Gx9.0 (Silicon Genetics), and expression data were 
normalized using “per chip normalization” and “per gene normalization” algorithms. Fold-change was 
calculated as the ratio between the average expression level under hypoxia and normoxia. We selected a 
modulated gene list of two-fold induction/inhibition with a false discovery rate of 0%. The significance 
of gene expression differences between the two experimental conditions was calculated using the Mann-
Whitney U-test. Only genes that passed the test at a confidence level of 95% (P<0.05) were considered 
significant. Complete data set for each microarray experiment was lodged in the Gene Expression 
Omnibus public repository at NCBI (www.ncbi.nlm.nih.gov/geo/) [accession Nr.GSE22282]. Gene 
Ontology (GO) data mining for biological process at level 1 was conducted online using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) software (http://david.niaid.nih.gov). 
HRE consensus elements consisting of a 4nt core (CGTG) flanked by degenerated sequences 
((T|G|C)(A|G)(CGTG)(C|G|A)(G|C|T)(G|T|C)(C|T|G)) were mapped in the promoter regions of genes 
represented in the chip, as detailed 12. 
Real-time RT-PCR 
Real time PCR (qRT-PCR) was performed on a 7500 Real Time PCR System (Applied), using 
SYBRGreen PCR Master Mix and sense/antisense oligonucleotide primers (TIBMolbiol) (listed in 
Table S1). Expression data were normalized on the values obtained in parallel for three reference genes 
(indicated in Table S1) selected among those not affected by hypoxia in the Affymetrix analysis using 
the Bestkeeper software, and relative expression values were calculated using Q-gene software, as 
detailed 21. 
Cross-linking of TREM-1-positive cells 
12-well flat-bottom tissue culture plates (Costar) precoated with 10µg/ml of agonist anti-TREM-1 mAb 
or control IgG1 were incubated ON at 37°C before seeding 8x10
5
 H-mDCs/well/ml of RPMI 1640 w/o 
cytokines. Plates were briefly spun at 1200 rpm to engage TREM-1. After 24hr stimulation under 
hypoxia, supernatants were harvested and tested for cytokine/chemokine content by ELISA. In a set of 
experiments, cells were plated in medium w/o FCS, plates centrifuged and incubated for 20 min at 37oC 






Western blot analysis and immunoprecipitation 
Total protein extracts were prepared as described 13, subjected to SDS-PAGE, transferred to PVDF 
membranes (Millipore), and probed with specified Abs. In a few experiments, lysates were subjected to 
immunoprecipitation with 10µg/ml anti-TREM-1 mAb or control IgG1 ON at 4°C, and protein G-
Sepharose 4B (GE-Healthcare) for 45 min at 4°C. Precipitates were separated by SDSPAGE and 
immunoblotted with anti-DAP12 mAb. Chemiluminescence detection was carried out with peroxidase-
conjugated goat anti-rabbit and anti-mouse Abs using an ECL kit (Pierce). 
ELISA 
Conditioned medium (CM) was replaced on day 3 or 4 of mDCs generation with fresh medium 
supplemented with cytokines for 24hr, and tested for soluble (s)TREM-1 content by ELISA (R&D 
Systems) after additional 24hr culture. sTREM-1 was also quantified in SF and plasma samples. TNFα, 
IL-6, IL-12p70, IL-10, IL-8, CCL4, and CCL5 were measured in CM from mDCs triggered with anti-
TREM-1 mAb or control mAb by specific ELISA (R&D Systems). Data were analyzed with the 
GraphPad Prism-5 Software. 
Statistical analysis 
Data are the mean ±SE of three independent experiments, unless differently specified. The Student’s t-
test was used to determine results’significance (p<0.05). sTREM-1 concentrations in SF and plasma 










Gene expression profile of hypoxic mDCs 
mDCs were generated by culturing human monocytes under normoxic and hypoxic conditions in the 
presence of GM-CSF/IL-4 for 4 days and a cocktail of pro-inflammatory stimuli for the last 48hr. As 
determined by flow cytometry (Fig.1), both mDCs and H-mDCs displayed the mature phenotype, 
characterized by high surface expression of CD1a differentiation marker, CD83 maturation marker, and 
CCR7 chemokine receptor, undetectable in fresh monocytes, and by upregulation of CD86 
costimulatory molecule and CXCR4 chemokine receptor, in agreement with previous observations 13. 
H-mDC transcriptional profile was then assessed by microarray analysis. Pairwise comparison between 
data sets from normoxic and hypoxic samples revealed differential modulation of a large number of 
transcripts. The majority of differentially expressed genes were identified as unique and named in the 
GenBankTM, whereas the remaining transcripts were either ESTs or hypothetical. After restricting the 
profile to sequences exhibiting ≥2-fold expression differences, we identified 563 up- and 402 down-
regulated genes by hypoxia (Fig.2), which were selected for further analysis. These results provided the 
first indication that mDCs and H-mDCs had a different gene expression signature.  
To gain insights into the nature of hypoxia-induced changes, selected genes were clustered into various 
functional categories according to GO data mining. We highlighted 33 interrelated functional pathways, 
containing a statistically significant portion of hypoxia-modulated genes (Fig.2). H-mDC transcriptional 
profile was mainly associated to cell growth, differentiation, and/or maturation, and angiogenesis 
regulation. Several upregulated genes fell into pathways implicated in signal transduction, metabolic 
processes, and apoptosis. Interestingly, a prominent set of upregulated genes had immunological 
relevance, coding for proteins involved in immune regulation, inflammatory responses, cell migration 
and adhesion. 
Characterization of hypoxia-inducible immune-related genes 
Among immune-related genes, profound differences were observed in the expression of a large cluster 
(63) of cell surface receptor-encoding genes (Table I). These include several PRRs critical to host 
defense, such as CD180, various complement receptor components, toll-like receptors (TLRs)-1 and -2, 
C-type lectin receptors CLEC-2D,-2B,-7A, and macrophage receptor with collagenous structure 
(MARCO). Of interest is also the upregulation of scavenger receptors implicated in the regulation of 
fatty acid and/or cholesterol uptake/transport, such as thrombospondin receptor (CD36) and 
apolipoprotein B48 receptor (APOB48R). A set of genes coding for costimulatory and adhesion/homing 
molecules was also upregulated, such as several integrin family members, L1 cell adhesion molecule 
(L1CAM/CD171), neuropilin-1 (NRP1), ADAM metallopeptidase 8 (ADAM8/CD156), 
platelet/endothelial cell adhesion molecule (PECAM-1/CD31), and lymphocyte adhesion molecule-1 
(LECAM1). Other hypoxia-inducible genes coded for immunoregulatory receptors, the most relevant of 
which are: Ig-Fc receptors, TREM-1, SLAM family member-9 (SLAMF9), blood dendritic cell antigen 
(BDCA3/CD141), leukocyte immunoglobulin-like receptors (LILR)-A1,-A2, and semaphorins 
(SEMA)-4B,-4D. 
These data suggest that hypoxia can exert a profound modulatory effect on mDC innate and adaptive 
immune functions. 
The possible relationship between gene inducibility by hypoxia and HRE presence in the promoter was 
then investigated by mapping HRE sequences in the first 2000 bases upstream the transcription 
initiation site. Interestingly, we found that ≈56% of upregulated genes contained at least one member of 
the HRE family in the promoter, whereas the others were HRE- (Table I), indicating that a remarkable 
portion of the hypoxic transcriptome does not require HIF-1 binding.  
To validate microarray results, mRNA levels for a subset of genes selected among those listed in Table I 
were quantified by qRT-PCR in pooled RNA from mDCs and H-mDCs generated from different donors 
(Fig.S1). A few known hypoxia target genes were analyzed in parallel as positive controls (indicated in 
Fig.S1). We found a ≈90% concordance between qRT-PCR and Affymetrix data with respect to the 
direction of the expression changes, although differences in the extent of modulation were observed for 
some genes. CD85, CD9, and CLEC2B upregulation by hypoxia was not confirmed by qRT-PCR. 
TREM-1 is expressed in hypoxic mDCs 
Among validated genes, TREM-1 was that displaying the highest expression difference in H-mDCs vs 
mDCs (Fig.S1). TREM-1 was previously reported to be selectively expressed in blood neutrophils and a 
subset of blood monocytes and tissue macrophages and to be completely downregulated during 
monocyte differentiation into DCs 16,17. Hence, we were interested in further investigating TREM-1 
regulation and functional significance in H-mDCs. 
To address the issue of donor-to-donor variability, we evaluated TREM-1 mRNA expression in H-
mDCs generated from five donors by qRT-PCR (Fig.3A). Expression of CAXII metalloenzyme was 
assessed in parallel as an index of response to hypoxia 22. TREM-1 transcript levels were significantly 
higher in H-mDCs than in mDCs from all tested samples, paralleling those of CAXII, with differences 
ranging from 23- to 516-fold among individual donors. In keeping with the mRNA data, marked 
TREM-1 immunoreactivity was observed by Western blot analysis in HmDCs lysates, whereas TREM-
1 was almost undetectable in mDCs (Fig.3B), suggesting that its expression is restricted to cells 
generated under hypoxia. 
TREM-1 surface expression was then measured by cytofluorimetry. The left panel of Figure 3C depicts 
CD83/TREM-1 staining pattern of mDCs and H-mDCs from a representative donor, and the right panel 
of Figure 3C shows the percentage of TREM-1+ cells in the CD83-gated population from eight 
individual samples at day 4 of culture. Fifty to 86% of CD83+ H-mDCs expressed TREM-1. 
Conversely, no TREM-1+ mDCs were detectable in any of the donors examined, confirming previous 
evidence 17. Immunophenotypic analysis of TREM-1+ and TREM-1- cells demonstrated a different 
expression profile of CD1c (BDCA-1) and CD141 (BDCA-3), two surface markers recently identified 
in functionally distinct subgroups of myeloid DCs (MDC1 and MDC2) in vivo 23, with a significantly 
(p<0.05) higher percentage of TREM-1+ H-mDCs displaying CD141 and a higher CD1c expression 
detectable on TREM-1- cells (Table S2), suggesting a correlation between TREM-1 and CD141 
expression. A soluble form of TREM-1 (sTREM-1) was described in biological fluids during 
inflammation 16,24. We evaluated sTREM-1 content in CM from mDCs and H-mDCs. sTREM-1 was 
released by H-mDCs but not by mDCs, ranging from 79 to 207 pg/10
6
 cells/ml in eight different donors 
(Fig.3D), consistent with the expression pattern of the membrane-bound form. 
H-mDCs reoxygenation by exposure to normoxic conditions (Reox) for 24hr resulted in a pronounced 
downregulation of TREM-1 mRNA levels compared to cells maintained under hypoxia for the same 
length of time (Fig.4A). Accordingly, reduction of TREM-1 surface expression was measured by FACS 
both in terms of mean fluorescence intensity and percentage of positive cells (Fig.4B) and was 
paralleled by a comparable decrease of sTREM-1 release into the supernatant (Fig.4C), suggesting that 
hypoxia simulatory effects on TREM-1 were reversible. The role of low pO2 as a stimulus for TREM-1 
in mDCs was further supported by data showing that TREM-1 mRNA (Fig.5A) and surface protein 
(Fig.5B) were induced in mDCs exposed to acute (24hr) hypoxia, although at levels and in a percentage 
of cells lower than those detectable in H-mDCs.  
DC exposure to hypoxia was previously shown to be associated with HIF-1αprotein accumulation and 
target gene induction 13-15. Given the presence of HRE in the gene promoter (Table I), we investigated 
the potential involvement of HIF-1αin TREM-1 hypoxic induction by RNA interference. As depicted in 
Supplemental Figure 2, high levels of HIF-1αwere present in mDCs cultured for 24hr under hypoxia 
and were associated with TREM-1 expression. HIF-1α silencing decreased TREM-1 protein levels, 
whereas it did not modify the expression of βactin used as an internal control. These data suggest that 
TREM-1 inducibility by hypoxia in mDCs is mediated at least in part by HIF-1α
TREM-1 cross-linking on H-mDCs promotes DAP12-signaling activation and proinflammatory 
cytokine and chemokine release 
TREM-1 is a transmembrane receptor which lacks signaling motifs in the short cytoplasmic tail and 
non-covalently associates with the adapter molecole, DAP12, for signal transduction in human 
monocytes and neutrophils 17,24,25. To confirm TREM-1 association with DAP12, 4-day HmDCs were 
subjected to immunoprecipitation with anti TREM-1 mAb, and the precipitates were analyzed by anti-
DAP12 immunoblotting. As shown in Figure 6A, TREM-1 paired with DAP12, consistent with a role 
for this protein in mediating TREM-1 signaling in H-mDCs. To determine whether TREM-1 was 
functionally competent, H-mDCs were plated on a plastic surface coated with an agonist mAb or control 
IgG for 20 min under hypoxia, and activation of DAP12-signaling pathway was assessed. TREM-1 
cross-linking resulted in increased phosphorylation of DAP12-linked molecules, ERK-1, Akt, and IBα, 
indicating that TREM-1 engagement can transduce activating signals in H-mDCs (Fig.6B). 
TREM-1 is an amplifier of the inflammatory response 17,24. Hence, we investigated whether its 
activation triggered proinflammatory cytokine and chemokine production by H-mDCs. 
Supernatants from H-mDCs were collected 24hr after stimulation with agonist anti-TREM-1 or control 
IgG1 under hypoxic conditions and analyzed for cytokine and chemokine content by ELISA (Fig.6C). 
TREM-1 cross-linking significantly enhanced TNF-α, IL-6, IL-12p70, CXCL8, CCL4, and CCL5 
secretion compared to Ig, whereas production of the anti-inflammatory cytokine IL-10 was not affected. 
No changes in cytokine secretion were observed upon triggering with an isotype matched anti-MHC-I 
mAb (data not shown), confirming that H-mDC activation by anti-TREM-1 mAb was not due to 
aspecific Fc receptor ligation. Overall, these data suggest that TREM-1 is a functional receptor 
selectively expressed by H-mDCs and not by the normoxic counterpart whose engagement can drive 
production of cytokines and chemokines involved in innate and adaptive immunity, raising the question 
of the existence of TREM-1+ mDCs in vivo. 
TREM-1 is expressed in vivo on H-mDCs recruited to the synovial fluid of JIA patients 
TREM-1 has been recently implicated in the pathogenesis of non-infectious inflammatory disorders, 
including rheumatoid arthritis (RA) 26,27. Hypoxia is a common feature of the inflamed rheumatoid 
synovium 8,28, and evidences suggest that DCs are enriched in arthritic joints playing a role in the 
initiation and perpetuation of the inflammatory process 23,29. To evaluate TREM-1+ mDCs occurrence in 
vivo, we investigated whether TREM-1 was expressed in synovial mDCs from children affected by JIA. 
We first analyzed plasma and SF samples obtained from JIA patients for sTREM-1 content by ELISA. 
As shown in Figure 7A, plasma sTREM concentrations in JIA patients (61-394 pg/ml) were 
significantly higher (P <0.01) than those in control subjects (12-16pg/ml) and were further increased (P 
value<0,001) in matched SF samples (1120-3800 pg/ml).  
These data are in line with previous observations in other forms of inflammatory arthritis, such as 
RA 26,27, indicating disease activity. 
SFMCs were then isolated from a subset of patients and analyzed for TREM-1 surface expression. HIF-
1αprotein was also evaluated in parallel by western blotting to confirm cell adaptation to the hypoxic 
synovial environment. SFMCs, but not paired PBMCs, constitutively accumulated high levels of HIF-
1α(Fig 7B), confirming recent observations 19,20. The presence of TREM-1+ mDCs in SFMCs was then 
determined by three-color flow cytometric analysis with mAbs to CD1a, CD83, and TREM-1. As 
shown in Figure 7C, a subset of SFMCs, ranging from 4.6%- to 6.6% in three different patients, 
expressed CD1a (left panels), confirming DC enrichment in JIA SF. A high proportion of DCs in JIA 
SF expressed CD83 (Fig.7C, right panels), comprising 42, 25, and 20% of the total CD1a-gated cells in 
patient 1, 3, and 6, respectively (upper + lower right quadrants). Noteworthily, 88, 60, and 80% of cells 
within the CD83+ subset expressed TREM-1, accounting for 37, 15, and 16% of the total CD1a-gated 
population (upper right quadrants). These findings provide the first evidence of the existence in a human 
hypoxic tissue in vivo of a population of CD83+ mDCs expressing TREM-1, correspondent to mDCs 
generated in vitro under low pO2, suggesting the potential relevance of this molecule as an in vivo 
















mDC development from monocytic precursors recruited at sites of inflammation and infection occurs in 
the setting of low pO2 5,6. The impact of the hypoxic microenvironment on DC maturation process is still 
controversial. This study characterizes the transcriptional profile of mDCs generated from human 
monocytes under chronic hypoxic conditions similar to those present in diseased tissues, demonstrating 
that H-mDCs are functionally reprogrammed through the differential expression of a large number of 
genes involved in innate and adaptive immunity.  
Futhermore, we define a new subpopulation of hypoxic mDCs characterized by the 
CD1a+/CD83+/TREM-1+ phenotype. 
Divergent effects of hypoxia on DC maturation were reported in previous studies based onthe 
expression of maturation markers, costimulatory molecules, chemokine receptors, and T cell priming 
ability. Mancino et al. showed that acute hypoxia impaired iDC phenotypic and functional maturation in 
response to LPS 14, whereas Rama et al. and Jantsch et al. demonstrated that it promoted their 
maturation both by itself5 and in combination with LPS 15. Two recent reports addressing the effects of 
chronic hypoxia suggested inhibition of monocyte-derived DC maturation 30,31. In contrast, our results 
indicate that chronic exposure to low pO2 does not substantially affect mDC phenotypic maturation, 
because comparable CD1a, CD83, CD86, CCR7 and CXCR4 surface expression was displayed by 
mDCs and H-mDCs, confirming and extending previous data by our group13 and by Zhao et al. 32. A 
possible explanation for these conflicting results could be the different experimental approaches used 
with regard to source and purity of DC precursors, differentiation/maturation protocols, degree and 
duration of the hypoxic stimulus, and difference of species (human vs mouse). 
Clustering of hypoxia-modulated genes according to GO data mining identified 33 interrelated 
functional categories, containing a statistically significant portion of genes controlling cell metabolism, 
differentiation/maturation, and functional properties. Interestingly, a large cluster of genes belonging to 
immune-related pathways was upregulated in H-mDCs respect to mDCs. 
These findings extend to mDCs the characteristic trend of response to hypoxia of other types of 
mononuclear phagocytes, including primary monocytes, monocyte-derived macrophages and iDCs 
12,21,33, emphasizing the critical contribution of reduced oxygenation to the control of immune responses. 
mDCs are critical for the induction of protective immunity to microbial invasion and the maintenance of 
self-tolerance 34. Their functions are tightly regulated by a complex network of inhibitory and activating 
signals transduced by a defined repertoire of cell surface receptors 4,24,35,36, and dysregulated expression 
of these molecules may result in an aberrant response characterized by amplification of inflammation 
and loss of tolerance 2,4,34. DC maturation under chronic hypoxia resulted in the upregulation of genes 
encoding various members of these receptor families. Profound changes were observed in genes coding 
for PRRs critical to host defense, which are endowed with the capability to recognize specific PAMPs 
on infectious agents and trigger proinflammatory cytokine production 36-38, suggesting enhanced 
inflammatory functions of mDCs generated in hypoxic than in normoxic areas. Upregulation of mRNA 
for the scavenger receptors, CD36 and APOB48R, is also of note and consistent with the view that 
hypoxia may exert a pathogenetic role in atherosclerosis7, because these molecules function as 
endocytic transporters for lipoproteins and phospholipids, contributing to lipid-loaded foam cell 
formation 39,40. mDC migration is known to be highly sensitive to microenvironmental changes 2-4. We 
observed higher expression of mRNA for several adhesion/homing receptors and costimulatory 
molecules in H-mDCs compared to mDCs. Given the role of the encoded proteins in cell-cell and cell-
matrix interactions, transendothelial migration and trafficking, and T cell costimulatory activity 41,42, it is 
likely that H-mDCs have an increased capacity to migrate to secondary lymphoid organs and activate 
adaptive immune responses than the normoxic counterparts. 
Hypoxia also affected the expression pattern of genes coding for immunoregulatory Ig-like receptor 
family members involved in the regulation of myeloid cell functions in innate and adaptive immunity. 
Of relevance, is the increased mRNA for Ig-Fc receptors. These are activating receptors characterized 
by “immunoreceptor tyrosine-based activating motifs” (ITAM) in their cytoplasmic domain (FcγRIIC, 
FcαR, FcεRI) or pairing with an ITAM-containing transmembrane adaptor proteins for signaling 
(FcγRIIIA), which trigger phagocytosis and immune complex clearance, inflammatory cytokine 
production, ADCC, and respiratory burst 43. Hypoxic upregulation of other genes encoding Ig family 
members, such as BDCA3, LILRA2, and SEMA4D 35,44,45, was also observed. These molecules 
modulate DC maturation, immunogenicity, cooperation with T cells, and pro-inflammatory cytokine 
production. Our results suggest that hypoxia can affect mDC functional behaviour in diseased tissues 
and potentially contribute to the pathogenesis of allergic inflammatory disorders and/or autoimmune 
diseases, which are associated with overexpression of these receptors 44-46. The challenge of future 
studies will be to validate these data in vivo.  
An intriguing finding of this study is the identification of TREM-1 as a hypoxia-inducible gene in 
mDCs. Previous reports have shown that TREM-1 is selectively expressed on neutrophils and on a 
subset of monocytes and tissue macrophages, where it can be markedly upregulated by various stimuli, 
such as TLR ligands and proinflammatory cytokines, whereas it is completely down-regulated during 
monocyte differentiation/maturation into DCs 16,17,24,25. Our results provide the first evidence that 
TREM-1 can be expressed in mDCs generated under chronic hypoxia. 
TREM-1 mRNA was consistently detected in H-mDCs from different donors and paralleled by 
expression of the membrane-bound receptor and release of its soluble form. Interestingly, TREM-
1mRNA and protein expression was also inducible upon mDC exposure to acute hypoxia, although at 
levels lower than those induced by chronic hypoxia, and was reversible, because cell reoxygenation 
resulted in TREM-1 downregulation. Consistent with these findings, HIF/HRE system appeared to be 
involved at least in part in TREM-1 hypoxic induction. These results suggest that TREM-1 expression 
in mDCs in vivo may vary dynamically with the degree of local oxygenation, which is quite 
heterogeneous and rapidly fluctuating in diseased tissues9, giving rise to distinct mDC subsets 
potentially endowed with different functional properties. 
TREM-1 expressed on H-mDC paired with DAP12 adapter protein and was biologically active, because 
its engagement resulted in the activation of DAP12-linked signaling, as shown by increased ERK-1 and 
Akt kinase phosphorylation. These data are in agreement with previous observations in primary 
monocytes and neutrophils 17,24,25. TREM-1 cross-linking on H-mDCs triggered secretion of TNFα, IL-
6, CXCL8, CCL4, and CCL5, which are important proinflammatory and chemotactic factors 4,13,21,29, 
and of IL-12p70, a Th1-inducing cytokines essential for adaptive immune responses against intracellular 
pathogens and tumors 4,34. These data support and extend previous findings implicating TREM-1 as an 
amplifier of inflammation 17,24 and suggest that the hypoxic environment enhances mDC ability to 
regulate leukocyte recruitment at inflammatory sites and Th1 priming by stimulating TREM-1 
expression. Increased nuclear levels of NF-kBα were observed in response to TREM-1 cross-linking in 
monocytes and neutrophils 25. NF-Bα proteins are sequestered in the cytoplasm by inhibitory proteins 
(IBαwhich become phosphorylated and subsequently degraded after cell activation, allowing NF-B 
nuclear translocation and activity47. Our data showing IBαphosphorylation in response to TREM-1 
crosslinking support a role for the NF-B pathway in TREM-1-mediated proinflammatory responses 
also in H-mDCs. 
Increased TREM-1 expression and sTREM-1 release were observed in several infectious and non-
infectious inflammatory disorders, suggesting a pathogenetic role for this molecule 16,17,24,26,27,48. Our 
data add to the growing list of diseases associated with TREM-1 overexpression, providing the first 
evidence of elevated sTREM-1 levels in JIA. JIA is the most common chronic pediatric rheumatic 
disease18, and sTREM-1 presence in JIA-SF is an index of the underlying inflammatory process whose 
persistence and amplification is dictated by the functional cooperation among several inflammatory cell 
populations recruited to the synovium of affected joints 28, including TREM-1+ 
monocytes/macrophages and neutrophils 26,27,48. We have recently documented the presence of reduced 
pO2 in the JIA synovium and the contribution of the hypoxic environment to the persistence of 
inflammation by triggering leukocyte recruitment and activation 19,20,28. The demonstration that SFMCs 
express HIF-1αconfirms the adaptation of synovial inflammatory cells to local hypoxia. Previous 
studies have demonstrated accumulation of both DC precursors and myeloid DC subsets in the SF and 
ST from children affected by JIA 23,28.  
Consistent with these findings, our immunophenotypical data demonstrated enrichment of cells 
expressing the DC marker CD1a in JIA synovial effusions, which comprised up to 6.6% of the total 
SFMC population. Although CD1a+ DCs had a predominantly immature phenotype (CD83-), a high 
percentage of mature (CD83+) DCs was also present in hypoxic JIA-SF, and the majority of cells in the 
CD83+ subset expressed TREM-1. Taken together with in vitro findings, the demonstration of TREM-1 
expression in vivo on mDCs present in hypoxic JIA-SF strongly suggest the potential relevance of this 
molecule as a marker of mDCs generated under hypoxic conditions.  
Furthermore, the observation that also the majority of cells belonging to the CD83- subset in JIASF was 
TREM-1+, indicates that TREM-1 expression is independent of the DC maturation stage, representing a 
common in vivo marker of hypoxic DCs. Sustained TREM-1 induction on synovial DCs by intra-
articular hypoxia may be of pathological relevance, representing a potential mechanism of amplification 
of synovial inflammation, and future studies will be aimed at assessing the role of TREM-1 putative 
ligand(s) 49 present in the inflamed arthritic synovium 50 in triggering DC proinflammatory cytokine and 
chemokine production. 
In conclusion, this study provides novel insights into the mechanisms linking low pO2 to the regulation 
of immune and inflammatory responses, leading to new perspectives of the role of hypoxia in 
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FIGURE 1. Phenotype of monocyte-derived mDCs generated under hypoxic conditions. 
Human monocytes were cultured for 48 hr with IL-4 and GM-CSF followed by incubation with the 
proinflammatory mediators, TNFα, IL-1β, IL-6, and PGE2 for additional 48 hr under 20% O2 (mDCs) or 
1% O2 (H-mDCs) conditions, and expression of the indicated cell surface molecules was analyzed by 
flow cytometry after 4 day culture, as described in the Methods. The expression profile of unstimulated 
monocytes is shown for comparison. Cells were gated according to their light scatter properties to 
exclude cell debris. Solid histograms represent the fluorescent profile of cells stained with specific 
FITC-conjugated Abs, whereas open histograms represent the fluorescent profile of cells stained with 
isotype-matched controls. Data are plotted as fluorescence intensity on a log scale vs the number of 
positive cells. In each histogram, the percentage of positive cells is indicated. Results are from one 
representative experiment out of ten performed with cells from different donors. 
FIGURE 2. Functional classification of hypoxia-responsive genes by GO data mining. The gene 
expression profile of H-mDCs vs mDCs was analyzed using high-density oligonucleotide arrays, as 
described in the Methods. Unique genes showing at least 2-fold change in expression levels between 
cells generated under hypoxic and normoxic conditions were selected and clustered in different KEGG 
pathways according to GO data mining for biological process at level 1 using the DAVID software. 
Based on this classification scheme, genes can be placed in more than one category if more than one 
function of the encoded protein was established. Bars on the right of the y axis represent upregulated 
genes; bars on the left of the y axis represent downregulated genes. Immunerelated pathways are 
highlighted in bold. 
FIGURE 3. TREM-1 expression in H-mDCs. mDCs and H-mDCs were generated from different 
donors, CM was replaced on day 3 of generation with fresh medium supplemented with cytokines, and 
TREM-1 was analyzed at day 4 of culture. (A) TREM-1 mRNA expression. Total RNA was reverse-
transcribed and tested for TREM-1 expression by qRT-PCR. CAXII mRNA levels were assayed in 
parallel as positive control. Expression changes were evaluated as detailed in the Methods. Data are 
expressed as mean normalized gene expression values, calculated on the basis of triplicate 
measurements for each experiment/donor, relative to the values obtained for the reference genes. (B) 
TREM-1 protein expression. Total cell lysates were prepared from mDCs generated from three of the 
donors shown in panel A under normoxic (-) or hypoxic (+) conditions. Proteins (100 (µg) were 
resolved on a 10% SDS-PAGE, and the blots were hybridized with Abs directed to TREM-1 and β-actin 
as a loading control. A representative immunoblot is shown. Strong bands are seen at ≈30 kDa, the 
expected TREM-1 molecular weight. (C) TREM-1 surface expression. mDCs and HmDCs were double-
stained with anti-CD83-FITC and anti-TREM-1-PE Abs and analyzed by flow cytometry on a 
FACScan, as specified in the Methods. Cells were electronically gated according to their light scatter 
properties to exclude cell debris. Left panel: results from one of eight independent experiments are 
shown as dot plots. The percentage of single and double-positive cells is indicated: TREM-1/CD83 
double-positive cells are contained in the upper right quadrant, whereas CD83 and TREM-1 single-
positive cells are contained in the lower right and upper left quadrants, respectively. Cells stained with 
control Abs were contained the lower left quadrants. Right panel: Data are expressed as percentage of 
TREM-1+ cells within CD83+ mDCs and H-mDCs generated from eight individual donors (dots). 
Horizontal lines represent median values for each group. p value by the Student’s t test is indicated. (D) 
sTREM-1 secretion. Cell free supernatants were harvested and assayed for sTREM content by ELISA. 
Data were obtained from the same preparations analyzed in panel C and are expressed as pg/1x10
6
 
cells/ml (dots). Horizontal lines represent median values for each group. p value by the Student’s t test 
is indicated. 
FIGURE 4. Effects of reoxygenation on TREM-1 expression. Four day H-mDCs were generated 
from different donors, CM was replaced with fresh medium supplemented with cytokines, and TREM-1 
was analyzed after additional 24 hr culture under 20% O2 (Reox). (A) TREM-1 (black bars) and CAXII 
(gray bars) mRNA expression was assessed by qRT-PCR. Data from one representative experiment of 
three performed are expressed as in the legend to Figure 3A. (B) TREM-1 surface expression was 
evaluated by flow cytometry. Solid histograms represent the fluorescent profile of TREM-1-expressing 
cells, whereas open histograms represent the fluorescent profile of cells stained with the isotype-
matched control Ab. The percentage of TREM-1+ cells and the mean fluorescent intensity (between 
brackets) are indicated. Results from one of three independently tested donors are shown. (C) sTREM-1 
release was measured by ELISA. Data from one representative experiment of three performed are 
expressed as pg/1x10
6
 cells/ml.  
FIGURE 5 Effects of acute hypoxia on TREM-1 expression. Four day mDCs were exposed to 
hypoxia for 24 hr and (A) TREM-1 (black bars) and CAXII (gray bars) mRNA expression was assessed 
by qRT-PCR. Data from one representative experiment of three performed are expressed as in the 
legend to Figure 3A. (B) TREM-1 surface expression was evaluated by flow cytometry. Solid 
histograms represent the fluorescent profile of TREM-1-expressing cells, whereas open histograms 
represent the fluorescent profile of cells stained with the isotype-matched control Ab. The percentage of 
TREM-1+ cells and the mean fluorescent intensity (between brackets) are indicated. Results from one of 
three independently tested donors are shown. 
FIGURE 6. Activation of H-mDCs by TREM-1 cross-linking. (A) mDCs were generated under 
hypoxic conditions from two different donors, and total cell lysates were subjected to 
immunoprecipitation with anti-TREM-1 mAb or control IgG1. The precipitates were resolved on a 12% 
SDS-PAGE and immunoblotted with anti-DAP12 mAb, as described in the Methods. DAP12 and Ig 
light chain (IgL) are indicated by arrows. Molecular weight markers are given at the side. (B,C) H-
mDCs were seeded onto plates pre-coated with agonist anti-TREM-1 mAb or control IgG1 at 10 µg/ml, 
after extensive washing to remove cytokines, and cultured for 20 min (B) or 24 hr (C) under hypoxic 
conditions. (B) Protein phosphorylation. Cell lysates (40 µg) were resolved on 10% SDS-PAGE, and 
immunoblotted with Abs anti-phospho (p)-ERK, Akt, and IkBαAbs against the non-phosphorylated 
forms (tot) were used as loading controls. Representative experiments performed with cells from two 
different donors are shown. T0 indicates H-mDCs from one of the donors not subjected to Ab cross-
linking, used as a negative control of phosphorylation. The figure was arranged by combining the lanes 
containing not-crosslinked samples (T0) with those containing samples subjected to cross-linking from 
differenta parts of the same gel. (C) Cytokine production. Conditioned medium was assayed for TNF-
α, IL-6, IL-12p70, IL-10, CXCL8, CCL4, and CCL5 content by specific ELISA. Results are expressed 
as pg or ng/8x10
5
 cells/ml and are represented as the mean ± SE of three different experiments. * 
P<0.05; **Pp<0.001; ***P<0.0001: values significantly different from those of H-mDCs cross-linked 
with IgG1. 
FIGURE 7. TREM-1 expression in vivo in hypoxic mDCs from JIA-SF. SF was collected from 
children affected by JIA, and SFMCs were purified as detailed in the Methods. (A) sTREM-1 
concentrations were quantified by ELISA in paired plasma and SF from eight JIA patients and plasma 
from five age-matched control subjects. Individual samples were run in triplicate. Boxes show the 




 percentiles, whiskers the highest and lowest values for each 
soubgroup. Bold horizontal lines represent median values. p value by the Wilcoxon rank test is 
indicated: *P<0.01 relative to plasma controls; **P<0.001 relative to plasma from JIA patients. (B) 
HIF-1αexpression was assessed by Western Blot analysis on whole protein extracts from three pairs of 
fresh PBMCs and SFMCs purified from a subset of the JIA patients shown in panel A. Protein (100 g) 
were resolved on a 8% SDS-PAGE, and the blots were hybridized with anti-HIF-1αmAb. β-actin was 
evaluated as a loading control. (C) Flow cytometric analysis of TREM-1 expression in SF-mDCs. 
SFMCs from the three JIA patients shown in panel B were stained with anti-CD1a-APC, CD83-FITC, 
and-TREM-1-PE Abs and analyzed on a FACScan. Cells were electronically gated according to their 
light scatter properties to exclude cell debris. The gated population was analyzed for CD1a positivity 
(left panels, region R1), and CD1a+ cells were then examined for CD83 and TREM-1 expression (right 
panels). Non-specific staining was corrected using isotype-matched Abs. Numbers represent the 
percentage of single and double-positive cells within the CD1a-gated population and are indicated for 
each patient: TREM-1/CD83 double positive cells are contained in the upper right quadrant, whereas 
CD83 and TREM-1 single-positivecells are contained in the lower right and upper left quadrants, 
respectively. Cells stained with control Abs are in the lower left quadrant. The percentage of TREM-1 
positive cells relative to the total number of CD83+ cells (representing TREM-1-expressing mDCs) was 
88, 60, and 80% in patient 1, 3, and 6, respectively, whereas the percentage of TREM-1 positive cells 
relative to the total number of CD83- cells (representing TREM-1-expressing iDCs) was 74, 80, and 
80% in patient 1, 3, and 6, respectively. 
 
Table II: Relative expression of genes encoding surface immunoregulatory/pattern-recognition receptors and costimulatory/adhesion molecules in H-mDCs 
vs N-mDCs^     
 
 
Gene Bank Gene symbol Full Name Main function(s) of gene Fold Increase§ 
Accession No.   product  
NM_018690 APOB48R* apolipoprotein B48 receptor Expressed on reticuloendothelial cells; binds the 
apolipoprotein B48 and regulates lipid transport into the cell 
2.9 
AJ277151 CD134 tumor necrosis factor receptor superfamily, member 4 Regulates  T-cell expansion and survival; activate NF-kB 
through its interaction with adaptor proteins TRAF2 and 
TRAF5 
2.1 
AW119113 CD141 (BDCA3) thrombomodulin, blood dendritic cell Ag  Expressed on DCs, associated with TH2-skewed immune 
responses, pathogenetic role in atopy and asthma  
11.4 
D37781 CD148* protein tyrosine phosphatase, receptor type, J Receptor PTP expressed in macrophages in response to pro-
inflammatory stimuli.; regulates cell spreading, cytoskeletal 
re-arrangements and chemotaxis; positive regulator of Src 
family kinases  
2.3 
NM_001109 CD156a  (ADAM8)* ADAM metallopeptidase domain 8  Membrane-anchored proteins implicated in cell-cell and cell-
matrix interactions, 
4.5 
AI653981 CD171 ( L1CAM)* L1 cell adhesion molecule  Costimulatory adhesion molecule belonging to the 
immunoglobulin supergene family; plays an important role in 
nervous system development, including neuronal migration 
and differentiation; regulates DC transendothelial migration 
and trafficking; implicated in motility and metastasis 
stimulation of several cancer cel types. 
6.7 
NM_005582 CD180 (RP105) CD180 antigen  Expressed on myeloid and B cells; belongs to the TLR4 
subfamily of TLRs, negative regulator of TLR4 signaling and 
of  innate immune responses to pathogens and danger:; 
activates  NF-kappa-B  
13.5 
NM_001877 CD21 (CR2) complement component (3d/Epstein Barr virus) receptor 2 Receptor for Epstein-Barr virus (EBV) on T and B cells; 
overexpressed on B cells and follicular DCs;  required for the 
generation of immune responses to T-dependent antigens. 
4.4 
AW241983 CD307 Fc receptor-like 5  Differentiation antigen expressed in B-lineage cells, involved 
in B-cell development and differentiation. May have an 
immunoregulatory role 
5 
M37780 CD31 (PECAM-1)* platelet/endothelial cell adhesion molecule  Cell adhesion molecule expressed on platelets, endothelial 
and other cells  
3 
NM_013447 CD312 (MR2) EGF-like domaincontaining, mucin-like, hormone receptor-like 2  Member of the adhesion-GPCR family differentially 
expressed during differentiation, maturation, and activation 
of myeloid cells; plays a role in their migration and adhesion  
3.8 
U90940 CD32 Fc fragment of IgG, low affinity IIc, receptor for  Expressed on myeloid cells; involved in effector and 
regulatory functions such as phagocytosis of immune 
complexes and modulation of antibody production by B-cells 
11 
NM_001772 CD33 CD33 antigen (gp67) Myeloid-restricted transmembrane protein of the sialic acid-
binding Ig-like lectin (Siglec) family marker of myeloid cell 
differentiation; negative regulator of myeloid cell activation 
and DC generation 
4.7 
NM_000573 CD35 (CR1 ) complement component (3b/4b) receptor 1 Member of the receptors of complement activation (RCA) 
family, expressed on follicular DCs, eritrocytes, and 
leukocytes; mediates cellular binding of complement-bound 
opsonins and immune complexes;. enhances  adaptive 
immune responses 
2.6 
AW299226 CD36* CD36 antigen (collagen type I receptor, thrombospondin receptor) Mulri-functional class B scavenger receptor; involved in the 
uptake of oxidized LDL, collagen, thrombospondin, anionic 
phospholipids, and apoptotic cells. Adhesion molecule 
5 
U87967 CD39 ( ENTPDase1) ectonucleoside triphosphate diphosphohydrolase   Surface enzyme that hydrolyzes nucleoside tri- and 
diphosphates , reduces inflammatory cell adhesion and 
trafficking and consequent tissue injury.; contributes to  
vascular homeostasis regulation 
2.7 
U94903 CD44 CD44 antigen   Receptor for hyaluronic acid, osteopontin, collagens, and 
matrix metalloproteinases (MMPs); involved in cell-cell 
interactions, cell adhesion and migration;; participates in  
lymphocyte activation, recirculation and homing, 
hematopoiesis, and tumor metastasis.  
2.7 
NM_001778 CD48* CD48 antigen (B-cell membrane protein) Member of the immunoglobulin supergene family, activation-
associated  glycoprotein expressed on leukocytes,  Ligand for 
CD2,  facilitates interaction between activated lymphocytes. 
Involved in the regulation of NK and T-cell activation 
2.7 
NM_000560 CD53 CD53 antigen Member of the tetraspanin family, complexes with integrins,  
plays a role in the regulation of leukocyte activation, growth 
and motility,  contributes to the transduction of CD2-
generated signals in T and NK cells 
3.6 
BE676623 CD71 Transferrin receptor (p90) Regulator of cellular uptake of iron and iron metabolism; IgA 
receptor expressed on DCs 
4.5 
AI681260 CD85 (LILRB1)* Leukocyte immunoglobulin-like receptor B1  Inhibitory leukocyte Ig-like receptor, expressed on myeloid 
lineage cells and up-regulated during DC differentiation; 
binds major histocompatibility complex class I; contains 
ITIM domains; inhibitor of immune and inflammatory 
responses 
2.6 
X74039 CD87 plasminogen activator, urokinase receptor Receptor for urokinase plasminogen activator (U-PA); 
regulates cell-surface plasminogen activation; mediates 
integrin-independent cell adhesion by  binding to  vitronectin, 
modulate the proliferative, adhesive, and migratory cellular 
phenotype  
3.8 
U43677 CD89* Fc fragment of IgA, receptor for Expressed on cells of myeloid lineage; ITAM-bearing 
receptor of the Fc region of immunoglobulins alpha; can 
mediate both pro- and anti-inflammatory functions of IgA; 
activator of Src family kinases  
55 
AK025016 CD9* CD9 antigen (p24) Member of the tetraspanin family,; facilitates the 
organization of multimolecular membrane complexes, 
including integrins; plays a role in leukocyte activation, 
differentiation, and migration; Involved in platelet activation 
and aggregation. 
8 
NM_012072 CD93 (C1qR1) complement component 1, q subcomponent, receptor 1 Defence collagen receptor for C1q,  mannose-binding lectin 
(MBL) and surfactant protein A; expressed on monocytes, 
neutrophils, endothelial cells, platelets, glial and stem cells; 
modulate phagocytosis and clearance of apoptotic cells; 
mediate s leucocyte-endothelial interactions 
8.6 
NM_002414 CD99* CD99 antigen Mediate leucocyte adhesion  amd  transendothelial migration 3.4 
BC005254 CLEC2B C-type lectin domain family 2, member B Member of the natural killer cell C-type lectin-like family of 
immunoregulatory receptors; platelet activation receptor  for 
snake venom, rhodocytin,, HIV, podoplanin; triggers platelet 
activation and aggregation; activator of Src and Syk families 
of tyrosine kinases;involved in tumor growth/metastatization. 
4.8 
AF285089 CLEC2D* C-type lectin domain family 2, member D Member of the natural killer cell  C-type lectin receptor 
family.;  pattern recogntion receptor expressed on DC 
subrypes, monocytes, macrophages, granulocytes,  and B 
cells; regulates the cross-talk between NK cells and APCs; 
mediates phagocytosis  and  proinflammatory cytokine 
production by myeloid cells; activator of Src and Syk 
families of tyrosine kinases;  
4.1 
AF313468 CLEC7A* C-type lectin domain family 7, member A (dectin-1)  Member of the C-type lectin-like family of 
immunoregulatory receptors; pattern recognition receptor for 
fungal beta-glucan predominantly expressed on DCs, 
monocytes, macrophages, neutrophils and microglia, ; 
activates phagocytosis, ROS, and cytokine production; DC-
maturaion and T cell costimulatory capacity  
2.9 
NM_020377 CYSLT2R cysteinyl leukotriene receptor 2 Member of the superfamily of G protein-coupled receptors; 
plays a major role in endocrine and cardiovascular systems; 
in immune cells expressed in eosinophils and macrophages,  
stimulates IL-8 secretion; up-regulates early inducible genes; 
mediates cell trafficking and innate immune responses; 
involved in the pathogenesis of chronic inflammatory 
diseases and allergic reactions  
2.9 
M74921 EDNRB* endothelin receptor type B G protein-coupled receptor; binds the vasoactive peptide, 
endothelin 
2.2 
AF213460 EPHA3 Ephrin receptor A3 Receptor for members of the ephrin-A family of receptor 
tyrosine kinases; mediates processes involved in cell-cell 
contact, cellular adhesion and angiogenesis, developmental 
remodeling and neuronal mapping 
4 
M34986 EPOR* erythropoietin receptor Member of the cytokine receptor family mainly expressed on 
the erythroid colony-forming 
units but also expressed in other hemopoietic cells; binds 
erythropoietin; immunostimulatory activities   
2.1 
NM_001432 EREG* epiregulin Member of the epidermal growth factor family,  binds EGFR 
and members of ErbB  tyrosine-kinase receptor family; 
mediates cell proliferation; promotes wound healing; the 
membrane-bound form  is involved in proinflammatory 
cytokine production by macrophages  
20.8 
NM_004106 FCER1G* Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide ITAM-containing subunit of the tetrameric high affinity IgE 
receptor and of other Fc receptors; expressed on mast cells 
and APCs; key molecule involved in allergic reactions 
mediated by IgE; involved in the regulation of several aspects 
of the immune response    
3.6 
NM_000570 FCGR3 (CD16a) * Fc fragment of IgG, low affinity IIIa, receptor  Intermediate affinity type 1 transmembrane glycoprotein of 
the Ig superfamily; expressed by a T lymphocyte subset, mast 
cells, NK cells, and phagocytes; activating receptor involved 
in phagocytosis, inflammatory mediator release, ADCC, and  
immune complex clearance  
9.6 
U81501 FPRL1* formyl peptide receptor-like 1 ; formyl peptide receptor-like 1 High affinity receptor for bacteria-derived and host-derived 
N-formyl-methionyl peptides; key player in innate immunity 
and host defense mechanisms against pathogen infection , 
mediates phagocyte chemotactic migration and IL-1 
production 
2.6 
AI246590 IRAK-2* interleukin-1 receptor-associated kinase 2 Members of the IRAK family of kinases; key components in 
the signal transduction pathways utilized by IL-1R and TLRs;  
critically involved in the regulation of intracellular signaling 
networks controlling inflammation, such as NF-kappaB 
activation  
9.7 
N95414 ITGA2  (CD49B)* Integrin, alpha 2  Receptor for laminin, collagen, fibronectin, and E-cadherin;  
involved in cell adhesion and cell-surface mediated 
signalling, generation and organization of newly synthesized 
extracellular matrix  
6.9 
NM_002205 ITGA5 (CD49)* integrin, alpha 5   Receptor for fibronectin and fibrinogen; involved cell 
adhesion to fibronectin and cell-surface mediated signalling 
3.6 
NM_002207 ITGA9 integrin, alpha 9 Receptor for VCAM1, tenascin and osteopontin; participates 
in cell adhesion and motility 
2 
NM_000889 ITGB7 integrin, beta 7 Interacts with the cell surface adhesion molecules 
MADCAM1, expressed on vascular endothelium , with 
8.3 
VCAM1 and fibronectin; plays a riole in adhesive 
interactions  
AW131039 ITGB8* Integrin, beta 8 Receptor for fibronectin; mediate cell-cell and cell-
extracellular matrix interaction 
3 
NM_000655 LECAM1 selectin L (lymphocyte adhesion molecule 1) Cell surface adhesion protein, belonging to a family of 
adhesion/homing receptors. required for binding and rolling 
of leucocytes on endothelial cells, facilitating their migration 
into secondary lymphoid organs and inflammation sites 
3 
AF025529 LILRA1 (LIR6)* leukocyte immunoglobulin-like receptor A1 Member of the leukocyte Ig-like immunoreceptor family  
expressed predominantly on monocytes/macrophages and B 
cells and at lower levels on dendritic cells and natural killer 
(NK) cells; it associates with Fcgamma R and acts as receptor 
for class I MHC antigens  
3.5 
NM_006866 LILRA2 (ILT1)* leukocyte immunoglobulin-like receptor A2 Member of the leukocyte Ig-like immunoreceptor family, 
selectively expressed on myeloid lineage cells, including DCs 
and in inflammatory tissues, such as RA synovium and 
lesions of lepromatous leprosy; functions as an activating 
receptor pairing with FcRg for signaling, promoting an 
inflammatory response  
6.4 
NM_002346 LY6 lymphocyte antigen 6 complex, locus E Glycosylphosphatidylinositol-anchored molecule that 
belongs to the Ly-6 family., also known  as stem cell antigen 
2 (SCA2); is a type I interferon-inducible gene;  highly 
expressed in a variety of human cancer cells  
2.5 
NM_006770 MARCO macrophage receptor with collagenous structure Member of the  class A scavenger receptor family, 
phagocytic pattern recognition receptor preferably expressed 
by phagocytes and upregulated in response to TLR agonists 
and Gram+/- bacteria, implicated in macrophage phagocytic 
activity and pro-inflammatory cytokine production; critical 
role  in host defense to pathogens; implicated in cell-cell 
recognition and modified LDL scavenging. 
3.7 
BE870509 MET (HGFR)* met proto-oncogene (hepatocyte growth factor receptor) Proto-oncogene encoding the trosine-kinase receptor for 
hepatocyte growth factor and scatter factor;  expressed in a 
variety of organs and cell types; plays a role in cell growth 
and motility in many physiologic and pathologic processes 
3.4 
AF280547 NRP1* neuropilin 1 Membrane-bound coreceptor to tyrosine kinase receptors for 
vascular endothelial growth factor, class 3 semaphorins, and 
placenta growth factor; involved in the control of cell growth 
and migration; plays a role in angiogenesis and axon 
guidance;  mediates contacts between DCs and T cells and is 
essential for the initiation of the primary immune response 
5.8 
M80436 PAFR platelet-activating factor receptor  G protein-coupled receptor  for platelet-activating factor 
(PAF);  transduces pleiotropic functions including cell 
motility, smooth muscle contraction, cytokine synthesis and 
2.8 
release;  implicated in diverse pathologic processes, such as 
allergy, asthma, septic shock, arterial thrombosis, and 
inflammatory processes 
S78505 PRLR* prolactin receptor Major mediator of prolactin effects on cell proliferation, 
survival, cytoskeletal modifications  and 
differentiation;expressed in a wide variety of cells and 
tissues, including PBMC. 
2.1 
NM_000956 PTGER2 prostaglandin E receptor 2  Receptor for prostaglandin E2, expressed on  macrophages 
and mDCs; activates the expression of multiple genes 
implicated in the regulation of immunity and inflammation; 
involved in CCR7-mediated DC migration  
3.7 
BE908995 MYADM (SB135)* myeloid-associated differentiation marker Selectively expressed in myeloid cells, including monocytes, 
DCs, promyeloid or monocytic leukemia cell lines;  marker 
of myeloid cell differentiation  
2.1 
AK026133 SEMA4B Semaphorin 4B Integral membrane protein with a Ig extracellular domain, 
widely expressed throughout the nervous system; provides 
axonal guidance cues during neuronal development  and 
regulates formation or function of synaptic specializations   
4.1 
NM_006378 SEMA4D ( CD100)* Semaphorin 4D Integral membrane protein with a Ig extracellular domain; 
controls proliferation, survival, and migration of cells of the 
nervous system and positively regulate angiogenesis through 
Plexin-B1  receptor; plays a role in both humoral and cellular 
immunity via interactions with  CD72; promotes DC 
maturation and function, B-cell aggregation and Ab 
production; Ag-specific T-cell activation, Mn migration, 
tumor-infiltrating Mf tumorigenic activity, T/B and T/DC 
interactions. 
3.1 
AJ130712 SIGLEC7 sialic acid binding Ig-like lectin 7 Member of the CD33-related Siglec recceptor family; highly 
expressed on NK cells and weakly on monocytes and a minor 
subpopulation of CD8 T lymphocytes; acts as an nhibitory 
receptor (ITIM motif). 
8 
NM_033438 SLAMF9* SLAM family member 9 Member of the signaling lymphocytic activation subfamily of 
the immunoglobulin superfamily; involved in  innate and 
acquired immuno responses through the regulation of 
multiple hematopoietic cell functions, including lymphocyte 
and monocyte/macrophage activation, NK killing,a DC 
maturaion, andplatelet aggregation  
12.2 
201666_at TIMP1* TIMP metallopeptidase inhibitor 1 inhibitor of most of the known MMPs, can  promote 
proliferation of several cell types and have an anti-apoptotic 
function  
15.1 
AL050262 TLR1* toll-like receptor 1 Member of the Toll-like receptor (TLR) family; expressed on 
cells of the innate immune system, plays a fundamental role 
in the recognition of pathogen-associated molecular patterns 
3.6 
(PAMPs) expressed on infectious agents and mediates the 
production of cytokines necessary for the activation of innate 
immunity   
NM_003264 TLR2* toll-like receptor 2 Member of the Toll-like receptor (TLR) family; expressed on 
cells of the innate immune system, plays an essential role in 
the innate immune recognition of pathogen-associated 
molecular patterns (PAMPs) expressed on infectious agents 
leading to the generation of an immune response; implicated 
in the pathogenesis of several  auto-immune and inflamatory 
diseases 
7.7 
NM_018643 TREM-1* triggering receptor expressed on myeloid cells 1 Ig superfamily immunoregulatory receptor expressed on 
monocytes/macrophages and neutrophils; stimulates their 
proinflammatory functions and acts as an inflamatory 
amplifier priming cells to respond to other stimuli via 
functional interaction with TLRs; regulation of integrin 
function via Plexin-A1.; involved in inflammatory diseases 
and septic shock.  
39.8 
1557444_at TREML3 triggering receptor expressed on myeloid cells-like 3 Ig superfamily immunoregulatory receptor expressed on  
myeloid cells, structurally related to 
the TREM genes and located in the TREM gene cluster on 
human chromosome 6  
5.9 
 
^Gene expression profiling was carried out independently on the RNA purified from three independent N- and H-mDC preparations, and comparative analysis of gene expression diferences between 
the two experimental conditions was conducted as described in the Materials and Methods. Each gene is given a representative GeneBank accession number, a common gene symbol, a brief gene 
description, and the fold increase value. Underlined genes were validated by qRT-PCR.                         
         
 
§The indicated values are calculated as the ratio of hypoxic/normoxic signals (mean of expression level of three experiments). Genes increased by ≥2 fold are shown. 
     
*Genes whose promoter contain members of the HRE family   
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